A study showed that a quiescent cell population in LSCs (Lin-CD34+) from CML patients was resistant to imatinib [14], suggesting that LSCs are insensitive to a BCR-ABL kinase inhibitor. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.